Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ViroPharma’s Failed Exclusivity Bid For Vancocin Could Spur Congress To Act

Apr 16 2012

• By Sue Sutter

Related Content

Labeling For Optimer's Dificid Includes Data On Ability To Sustain Cure Post-Treatment

May 27 2011

Senate Accelerated Approval Draft Needs “FAST” Changes, House Members Say

Apr 11 2012

<em>Vancocin</em> Generics Launch As FDA Finds ViroPharma’s Label Fails “Significant New Use” Test

Apr 11 2012

Orphan Antibiotics? Woodcock Says It May Be Possible If IDSA’s New Pathway Is Implemented

Mar 31 2012

“Old” Antibiotics May Get Exclusivity Under New Law; 10 Drugs Could Benefit

Oct 06 2008

Related Companies

ViroPharma Inc.

Additional Topics

United States Drug Approval Standards BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window